The Cost Effectiveness of Bisphosphonates for the Prevention and Treatment of Osteoporosis
暂无分享,去创建一个
Rachael L. Fleurence | R. Fleurence | C. Iglesias | Cynthia P. Iglesias | Jeanene M. Johnson | Jeanene Johnson
[1] O. Johnell,et al. Cost-effectiveness of risedronate for the treatment of osteoporosis and prevention of fractures in postmenopausal women , 2004, Osteoporosis International.
[2] C. Kooperberg,et al. Effect of estrogen plus progestin on stroke in postmenopausal women: the Women's Health Initiative: a randomized trial. , 2003, JAMA.
[3] S. Boonen,et al. The diagnosis and treatment of male osteoporosis: Defining, assessing, and preventing skeletal fragility in men. , 2007, European journal of internal medicine.
[4] J. Kanis,et al. Epidemiology of osteoporosis. , 1992, Bone.
[5] O. Johnell,et al. Cost effectiveness of alendronate for the treatment of male osteoporosis in Sweden. , 2004, Bone.
[6] G. Guyatt,et al. Summary of meta-analyses of therapies for postmenopausal osteoporosis and the relationship between bone density and fractures. , 2002, Endocrinology and metabolism clinics of North America.
[7] D. Gyrd-Hansen,et al. Subchronic toxicity of baltic herring oil and its fractions in the rat (III) bone tissue composition and dimension, and ratio of n-6/n-3 fatty acids in serum phospholipids. , 2005 .
[8] B. Hillner,et al. A cost effectiveness analysis of calcium and vitamin D supplementation, etidronate, and alendronate in the prevention of vertebral fractures in women treated with glucocorticoids. , 2003, The Journal of rheumatology.
[9] E. Loeliger. Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis. , 1995, The American journal of medicine.
[10] John Robbins,et al. National cross sectional survey to determine whether the decision to delivery interval is critical in emergency caesarean section , 2004, BMJ : British Medical Journal.
[11] A. Tosteson,et al. Incidence and Economic Burden of Osteoporosis‐Related Fractures in the United States, 2005–2025 , 2007, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[12] D. F. Gallagher,et al. British National Formulary Online. www.bnf.org , 2003 .
[13] R. Lindsay. Prevention of osteoporosis. , 1987, Clinical orthopaedics and related research.
[14] H. Fleisch,et al. Bisphosphonates: preclinical aspects and use in osteoporosis. , 1997, Annals of medicine.
[15] E De Nigris,et al. A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis. , 2005, Health technology assessment.
[16] J A Kanis,et al. Treatment of established osteoporosis: a systematic review and cost-utility analysis. , 2002, Health technology assessment.
[17] S. Cummings,et al. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. , 2006, JAMA.
[18] Jacques P. Brown,et al. Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. , 1997, The New England journal of medicine.
[19] M. Brown,et al. Cost Effectiveness of Bone Density Measurements , 2001 .
[20] Robert Kane,et al. Cost-Effectiveness of Alendronate Therapy for Osteopenic Postmenopausal Women , 2005, Annals of Internal Medicine.
[21] P. Saville,et al. Cost-effectiveness Strategies to Treat Osteoporosis in Elderly Women , 2006, Southern medical journal.
[22] R. Francis,et al. A comparison of the effectiveness and cost of treatment for vertebral fractures in women. , 1995, British journal of rheumatology.
[23] G. Storvik,et al. A Bayesian analysis of bisphosphonate effects and cost‐effectiveness in post‐menopausal osteoporosis , 2000 .
[24] O. Johnell,et al. Prevention of osteoporosis: Cost-effectiveness of different pharmaceutical treatments , 2005, Osteoporosis International.
[25] R. Rizzoli,et al. Glucocorticoid-induced osteoporosis and its treatment. , 2006, Clinical orthopaedics and related research.
[26] D. Grady. Postmenopausal hormones--therapy for symptoms only. , 2003, The New England journal of medicine.
[27] Ego Seeman,et al. Prevention of nonvertebral fractures by alendronate. A meta-analysis. Alendronate Osteoporosis Treatment Study Groups. , 1997, JAMA.
[28] G. Torrance,et al. Cost Effectiveness of Multi-Therapy Treatment Strategies in the Prevention of Vertebral Fractures in Postmenopausal Women with Osteoporosis , 1998, PharmacoEconomics.
[29] K. Ensrud,et al. Universal Bone Densitometry Screening Combined with Alendronate Therapy for Those Diagnosed with Osteoporosis Is Highly Cost‐Effective for Elderly Women , 2005, Journal of the American Geriatrics Society.
[30] Dan Greenberg,et al. Bias in published cost effectiveness studies: systematic review , 2006, BMJ : British Medical Journal.
[31] Lee R. Mobley,et al. Cost-Effectiveness of Osteoporosis Screening and Treatment with Hormone Replacement Therapy, Raloxifene, or Alendronate , 2006, Medical decision making : an international journal of the Society for Medical Decision Making.
[32] Charles Kooperberg,et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. , 2002, JAMA.
[33] W. Mysiw,et al. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. , 1990, The New England journal of medicine.
[34] Jacques P. Brown,et al. Alendronate for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis , 1998 .
[35] A. Tosteson,et al. Towards a reference case for economic evaluation of osteoporosis treatments. , 2003, The Journal of rheumatology. Supplement.
[36] James G. Anderson. Surgical Training, Error , 2004 .
[37] O. Johnell,et al. Epidemiology of osteoporotic fractures , 2005, Osteoporosis International.
[38] C. Cooper,et al. Population-based study of survival after osteoporotic fractures. , 1993, American journal of epidemiology.
[39] J Dequeker,et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. , 1995, The New England journal of medicine.
[40] C. Cooper,et al. Oral vitamin D3 and calcium for secondary prevention of low-trauma fractures in elderly people (Randomised Evaluation of Calcium Or vitamin D, RECORD): a randomised placebo-controlled trial , 2005, The Lancet.
[41] L. Avioli,et al. Coherence therapy does not prevent axial bone loss in osteoporotic women: a preliminary comparative study. , 1988, The Journal of clinical endocrinology and metabolism.
[42] R. Kane,et al. Potential cost-effective use of spine radiographs to detect vertebral deformity and select osteopenic post-menopausal women for amino-bisphosphonate therapy , 2005, Osteoporosis International.
[43] Prevention of nonvertebral fractures by alendronate. A meta-analysis. Alendronate Osteoporosis Treatment Study Groups. , 1997 .
[44] K. Kuntz,et al. Should postmenopausal women with rheumatoid arthritis who are starting corticosteroid treatment be screened for osteoporosis? A cost-effectiveness analysis. , 2000, Arthritis and rheumatism.
[45] A. Oestreich,et al. Health-economic comparison of three recommended drugs for the treatment of osteoporosis. , 2004, International journal of clinical pharmacology research.
[46] P. L. Bergsagel,et al. Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma. , 2006, Mayo Clinic proceedings.
[47] Andrea Manca,et al. Assessing Generalisability in Model-Based Economic Evaluation Studies , 2012, PharmacoEconomics.
[48] G. Guyatt,et al. Meta-analyses of therapies for postmenopausal osteoporosis. II. Meta-analysis of alendronate for the treatment of postmenopausal women. , 2002, Endocrine reviews.
[49] C. Cooper,et al. Epidemiology of Osteoporotic Fractures , 2000, Hormone Research in Paediatrics.
[50] David J Torgerson,et al. Primary care Randomised controlled trial of calcium and supplementation with cholecalciferol (vitamin D 3 ) for prevention of fractures in primary care , 2005 .
[51] H K Genant,et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. , 1999, JAMA.
[52] S. Cummings,et al. Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group. , 2000, The Journal of clinical endocrinology and metabolism.
[53] The use of etidronate and calcium versus calcium alone in the treatment of postmenopausal osteopenia: Results of three years of treatment , 2005, Osteoporosis International.
[54] S. Wimalawansa. A four-year randomized controlled trial of hormone replacement and bisphosphonate, alone or in combination, in women with postmenopausal osteoporosis. , 1998, The American journal of medicine.
[55] S. Cummings,et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures , 1996, The Lancet.
[56] D. Torgerson,et al. Economic evaluations of interventions for the prevention and treatment of osteoporosis: a structured review of the literature , 2005, Osteoporosis International.
[57] D. Felsenberg,et al. Pharmacoeconomic analysis of osteoporosis treatment with risedronate. , 2003, International journal of clinical pharmacology research.
[58] P Geusens,et al. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. , 2001, The New England journal of medicine.
[59] H. Mulder,et al. Intermittent cyclical etidronate in the prevention of corticosteroid-induced bone loss. , 1994, British journal of rheumatology.
[61] C. Cooper,et al. Epidemiology of fractures in England and Wales. , 2001, Bone.
[62] J Raftery,et al. NICE: faster access to modern treatments? Analysis of guidance on health technologies , 2001, BMJ : British Medical Journal.
[63] C. Rubio-Terrés,et al. Análisis farmacoeconómico del tratamiento de la osteoporosis postmenopáusica con risedronato o alendronato , 2002 .
[64] B. Luce,et al. The return on investment in health care: from 1980 to 2000. , 2006, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[65] M. Hooper,et al. Randomized Trial of the Effects of Risedronate on Vertebral Fractures in Women with Established Postmenopausal Osteoporosis , 2000, Osteoporosis International.
[66] Milton C Weinstein,et al. Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices--Modeling Studies. , 2003, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[67] Karl Claxton,et al. Assessing Quality in Decision Analytic Cost-Effectiveness Models , 2000, PharmacoEconomics.
[68] O. Johnell,et al. Cost Effectiveness of Alendronate (Fosamax®) for the Treatment of Osteoporosis and Prevention of Fractures , 2012, PharmacoEconomics.
[69] C. Cooper,et al. Epidemiology and public health impact of osteoporosis. , 1993, Bailliere's clinical rheumatology.
[70] D J Torgerson,et al. The cost utility of bisphosphonate treatment in established osteoporosis. , 2002, QJM : monthly journal of the Association of Physicians.
[71] Kay Dickersin,et al. Osteoporosis prevention, diagnosis, and therapy. , 2000, NIH consensus statement.
[72] R. Francis,et al. Randomized controlled trial of hip protectors among women living in the community , 2004, Osteoporosis International.
[73] D. Torgerson,et al. The Cost of Treating Osteoporotic Fractures in the United Kingdom Female Population , 1998, Osteoporosis International.
[74] C. Mullins,et al. Modeling the Annual Costs of Postmenopausal Prevention Therapy: Raloxifene, Alendronate, or Estrogen-Progestin Therapy , 2003, Journal of managed care pharmacy : JMCP.
[75] Gordon Guyatt,et al. Meta-analyses of therapies for postmenopausal osteoporosis. IX: Summary of meta-analyses of therapies for postmenopausal osteoporosis. , 2002, Endocrine reviews.
[76] G. Guyatt,et al. A Meta-analysis of Etidronate for the Treatment of Postmenopausal Osteoporosis , 2001, Osteoporosis International.
[77] Bess Dawson-Hughes,et al. Fracture prevention with vitamin D supplementation: a meta-analysis of randomized controlled trials. , 2005, JAMA.
[78] H. Genant,et al. Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. , 1990, The New England journal of medicine.
[79] Charles L. Bosk,et al. Forgive and remember : managing medical failure , 1980 .
[80] Peter Tugwell,et al. Cost Effectiveness of Nasal Calcitonin in Postmenopausal Women , 2012, PharmacoEconomics.
[81] A. LaCroix,et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. , 1998, JAMA.